Athenex, Inc. to Report First Quarter 2019 Earnings Results on May 9, 2019
April 25 2019 - 6:00AM
Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company
dedicated to the discovery, development and commercialization of
novel therapies for the treatment of cancer and related conditions,
today announced that it will release first quarter ended March 31,
2019 financial results on May 9, 2019 before the market opens. The
Company will host a conference call and live audio webcast on
Thursday, May 9, 2019, at 8:00am Eastern Time to discuss the
financial results and provide a business update.
To participate in the call, dial 877-407-0784 (domestic) or
201-689-8560 (international) fifteen minutes before the conference
call begins and reference the conference passcode 13689379.
The live conference call and replay can also be accessed via audio
webcast at the Investor Relations section of the Company’s website,
located at http://ir.athenex.com/.
About Athenex, Inc. Founded in
2003, Athenex, Inc. is a global clinical stage
biopharmaceutical company dedicated to becoming a leader in the
discovery, development and commercialization of next generation
drugs for the treatment of cancer. Athenex is organized
around three platforms, including an Oncology Innovation Platform,
a Commercial Platform and a Global Supply Chain Platform. The
Company’s current clinical pipeline is derived from four different
platform technologies: (1) Orascovery, based on non-absorbed
P-glycoprotein inhibitor, (2) Src kinase inhibition, (3) T-cell
receptor-engineered T-cells (TCR-T), and (4) Arginine deprivation
therapy. Athenex’s employees worldwide are dedicated to improving
the lives of cancer patients by creating more active and tolerable
treatments. Athenex has offices
in Buffalo and Clarence, New York; Cranford,
New Jersey; Houston, Texas; Chicago, Illinois; Hong
Kong; Taipei, Taiwan; and multiple locations
in Chongqing, China. For more information, please
visit www.athenex.com.
CONTACTSTim McCarthyManaging Director, LifeSci
Advisors, LLCTel: +1 716-427-2952 Direct: +1 212-915-2564
Athenex, Inc.:Randoll SzeChief Financial OfficerEmail:
randollsze@athenex.com
Jacqueline LiCorporate Development and Investor RelationsEmail:
jacquelineli@athenex.com
Athenex (NASDAQ:ATNX)
Historical Stock Chart
From Apr 2024 to May 2024
Athenex (NASDAQ:ATNX)
Historical Stock Chart
From May 2023 to May 2024